(Q37848663)

24 August 2017

1 reference

title

Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer (English)

1 reference

24 August 2017

0 references

Olli-Pekka Kallioniemi

series ordinal

3

1 reference

24 August 2017

Samir M Hanash

1

1 reference

PubMed ID

21364687

24 August 2017

Christina S Baik

series ordinal

2

1 reference

PubMed ID

21364687

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

142-150

1 reference

24 August 2017

3

1 reference

Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Cost of breast-related care in the year following false positive screening mammograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Early Lung Cancer Action Project: overall design and findings from baseline screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Early lung cancer action project: initial findings on repeat screenings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Malignant versus benign nodules at CT screening for lung cancer: comparison of thin-section CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Lung cancer screening with CT: Mayo Clinic experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

CT screening for lung cancer: five-year prospective experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Biomarkers for the lung cancer diagnosis and their advances in proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Biomarkers for lung cancer: clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Multiplexed microsphere-based flow cytometric immunoassays for human cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Serum autoantibodies as biomarkers for early cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Mutation-associated fusion cancer genes in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Development of personalized tumor biomarkers using massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Circulating nucleic acids as a potential source for cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

DNA methylation based biomarkers in non-invasive cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

miRNAs, cancer, and stem cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Circulating microRNAs as stable blood-based markers for cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Detection of microRNA expression in human peripheral blood microvesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Metabolomics: available results, current research projects in breast cancer, and future applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Metabolomics: moving to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

An integrative genomics approach to infer causal associations between gene expression and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Circulating tumour cells in cancer patients: challenges and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Molecular mechanisms of metastasis in breast cancer--clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Combination of multiple mRNA markers (PTTG1, Survivin, UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Circulating tumour cells in clinical practice: Methods of detection and possible characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

21 January 2018

Cancer micrometastases

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Network-based classification of breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Panel of serum biomarkers for the diagnosis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Autoantibodies in breast cancer: their use as an aid to early diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

31 March 2020

Metabolomics of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Biological markers in lung cancer: A clinician's perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.220

Lung cancer screening with low-dose computed tomography: Canadian experience.

31 March 2020

1 reference

12 December 2020

Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial

1 reference

12 December 2020

Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.

1 reference

12 December 2020

Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy.

1 reference

12 December 2020

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

1 reference

12 December 2020

Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer

1 reference

12 December 2020

Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer

1 reference

12 December 2020

MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients

1 reference

12 December 2020

Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool

1 reference

12 December 2020

10.1038/NRCLINONC.2010.220

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21364687